Good morning :)
Place Order
Add to Watchlist

Glenmark Pharmaceuticals Ltd

GLENMARK Share Price

2,224.100.09% (-2.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹62,820 cr, stock is ranked 164

Stock is 2.43x as volatile as Nifty

GLENMARK Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹62,820 cr, stock is ranked 164

Stock is 2.43x as volatile as Nifty

GLENMARK Performance & Key Metrics

GLENMARK Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
59.998.010.11%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.806.510.80%

GLENMARK Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
91%
Analysts have suggested that investors can buy this stock

from 11 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

GLENMARK Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Investor Presentation

View older View older 

May 23, 2025

PDF
View Older Presentations

GLENMARK Similar Stocks (Peers)

Compare with peers Compare with peers 

GLENMARK Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.93
37.93
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
PE Ratio
22.84
22.84
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
PE Ratio
60.91
60.91
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
PE Ratio
54.95
54.95
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
PE Ratio
18.55
18.55
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
Compare with Peers

GLENMARK Forecast

GLENMARK Forecasts

Price

Revenue

Earnings

GLENMARK

GLENMARK

Income

Balance Sheet

Cash Flow

GLENMARK Income Statement

GLENMARK Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 4.4%, vs industry avg of 10.15%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 4.31% to 3.22%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 6.18%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue9,116.789,165.8210,240.7910,833.4511,038.6912,471.5712,339.1013,050.4213,435.4613,435.46
Raw Materialssubtract3,073.932,904.863,421.013,570.563,809.434,396.424,498.194,608.9911,343.1811,343.17
Power & Fuel Costsubtract127.02137.48165.26173.69164.67200.64111.75124.00
Employee Costsubtract1,640.811,871.842,056.072,254.782,343.712,447.422,600.782,868.14
Selling & Administrative Expensessubtract1,589.861,523.271,750.211,667.021,453.551,543.271,752.301,708.60
Operating & Other expensessubtract692.041,021.60887.121,276.841,088.191,657.761,751.062,208.99
Depreciation/Amortizationsubtract264.37301.88325.91417.17443.55486.72569.17581.91486.01486.02
Interest & Other Itemssubtract237.32285.57334.59377.32353.11298.10349.04515.97207.07207.06
Taxes & Other Itemssubtract382.67315.46375.63320.11412.44499.54409.561,935.49352.12352.10
EPS39.2928.4932.7827.5034.3833.3710.53-53.2237.1137.11
DPS2.002.002.002.502.502.502.502.502.502.50
Payout ratio0.050.070.060.090.070.070.240.070.07

GLENMARK Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 23PDF
Feb 14PDF
Nov 14PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Sep 21PDF
Aug 11PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 19PDF
Feb 10PDF
Nov 17PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF

Investor Presentation

Jul 19PDF
FY 2016FY 2016

Annual report

PDF

Investor Presentation

Jan 12PDF
FY 2015FY 2015

Annual report

PDF
 

GLENMARK Stock Peers

GLENMARK Past Performance & Peer Comparison

GLENMARK Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Glenmark Pharmaceuticals Ltd60.008.010.11%
Sun Pharmaceutical Industries Ltd37.935.720.93%
Cipla Ltd22.843.851.07%
Torrent Pharmaceuticals Ltd60.9115.340.93%

GLENMARK Stock Price Comparison

Compare GLENMARK with any stock or ETF
Compare GLENMARK with any stock or ETF
GLENMARK
Loading...

GLENMARK Holdings

GLENMARK Shareholdings

GLENMARK Promoter Holdings Trend

GLENMARK Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

GLENMARK Institutional Holdings Trend

GLENMARK Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

GLENMARK Shareholding Pattern

GLENMARK Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.65%12.86%1.74%23.16%15.59%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

GLENMARK Shareholding History

GLENMARK Shareholding History

Dec '23MarJunSepDec '24Mar23.71%21.38%20.98%23.05%23.51%23.16%

Mutual Funds Invested in GLENMARK

Mutual Funds Invested in GLENMARK

No mutual funds holding trends are available

Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.9727%2.21%0.35%7/81 (+2)
0.7732%1.18%-0.22%64/112 (-6)
0.5857%1.38%-0.26%49/91 (0)

Compare 3-month MF holding change on Screener

GLENMARK Insider Trades & Bulk Stock Deals

GLENMARK Insider Trades & Bulk Stock Deals

Loading...

smallcases containing GLENMARK stock

smallcases containing GLENMARK stock

Looks like this stock is not in any smallcase yet.

GLENMARK Events

GLENMARK Events

GLENMARK Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

GLENMARK has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.13 every year

Dividends

Corp. Actions

Announcements

Legal Orders

GLENMARK Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

GLENMARK has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.13 every year

GLENMARK Upcoming Dividends

GLENMARK Upcoming Dividends

No upcoming dividends are available

GLENMARK Past Dividends

GLENMARK Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateSep 12, 2022

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 12, 2022

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateSep 17, 2020

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 17, 2020

GLENMARK Stock News & Opinions

GLENMARK Stock News & Opinions

Spotlight
Glenmark Pharmaceuticals Ltd up for third consecutive session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2214.7, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 25050.1. The Sensex is at 82139.43, down 0.44%. Glenmark Pharmaceuticals Ltd has gained around 31.56% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2% in last one month and is currently quoting at 22225.9, up 1.15% on the day. The volume in the stock stood at 27.13 lakh shares today, compared to the daily average of 18.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2223, up 1.92% on the day. Glenmark Pharmaceuticals Ltd is up 57.28% in last one year as compared to a 1.88% jump in NIFTY and a 7.85% jump in the Nifty Pharma index.The PE of the stock is 35.29 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 day agoCapital Market - Live
Spotlight
Glenmark Pharma receives warning letter from USFDA for Indore facility

The USFDA inspection was conducted between 3 February and 14 February 2025. In an official filing, the company stated that it does not anticipate the warning letter will disrupt supply chains or affect revenues generated from the Indore facility. Glenmark emphasized its commitment to addressing the FDA's concerns promptly and working closely with the regulator to resolve the issues. The company further clarified that there were no observations related to data integrity during the inspection. Glenmark reaffirmed its dedication to maintaining the highest quality and compliance standards, including adherence to Current Good Manufacturing Practices (CGMP), across all its facilities. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. The scrip shed 0.56% to Rs 2,169.30 on the BSE. Powered by Capital Market - Live

2 days agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd leads gainers in 'A' group

Netweb Technologies India Ltd, Globus Spirits Ltd, VST Industries Ltd and Jaiprakash Power Ventures Ltd are among the other gainers in the BSE's 'A' group today, 11 July 2025.Glenmark Pharmaceuticals Ltd spiked 15.00% to Rs 2190.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.04 lakh shares were traded on the counter so far as against the average daily volumes of 21923 shares in the past one month. Netweb Technologies India Ltd surged 5.47% to Rs 1912.4. The stock was the second biggest gainer in 'A' group. On the BSE, 1.02 lakh shares were traded on the counter so far as against the average daily volumes of 21540 shares in the past one month. Globus Spirits Ltd soared 5.30% to Rs 1011.55. The stock was the third biggest gainer in 'A' group. On the BSE, 30438 shares were traded on the counter so far as against the average daily volumes of 5407 shares in the past one month. VST Industries Ltd gained 5.30% to Rs 295.85. The stock was the fourth biggest gainer in 'A' group. On the BSE, 57356 shares were traded on the counter so far as against the average daily volumes of 52831 shares in the past one month. Jaiprakash Power Ventures Ltd exploded 5.13% to Rs 24.2. The stock was the fifth biggest gainer in 'A' group. On the BSE, 316.68 lakh shares were traded on the counter so far as against the average daily volumes of 197.32 lakh shares in the past one month. Powered by Capital Market - Live

4 days agoCapital Market - Live
Spotlight
Glenmark Pharma soars on AbbVie licensing deal for cancer therapy ISB 2001

The announcement follows a major licensing agreement with U.S. biopharma giant AbbVie. Under the terms of the agreement, IGI will collaborate with AbbVie to develop, manufacture, and commercialize ISB 2001, a first-in-class trispecific T-cell engager designed to treat multiple myeloma. AbbVie will handle development and commercialization in North America, Europe, Japan, and Greater China. Glenmark Pharmaceuticals will take charge of manufacturing and marketing the therapy in Emerging Markets, including Asia (excluding key developed markets), Latin America, the Russia/CIS region, the Middle East, Africa, Australia, New Zealand, and South Korea. ISB 2001, currently in Phase 1 clinical development, targets BCMA and CD38 on myeloma cells and CD3 on T cells. Developed using IGI's proprietary BEAT protein platform, the asset is engineered to enhance efficacy even at low antigen expression levels while aiming to improve safety over traditional bispecific antibodies. Data presented at the 2025 ASCO Annual Meeting showed promising results: a 79% overall response rate and 30% complete/stringent complete response in a heavily pretreated patient population. The therapy has also received Orphan Drug Designation (July 2023) and Fast Track Designation (May 2025) from the U.S. FDA for relapsed/refractory multiple myeloma. With this landmark deal, Glenmark is poised to strengthen its footprint in the global oncology market while expanding patient access to next-gen immunotherapies across high-need regions. Our collaboration with AbbVie and Glenmark reflects IGI's mission to accelerate access to transformative multispecifics for patients worldwide, said Cyril Konto, M.D., President, Executive Director and CEO of IGI. AbbVie's reach in major markets combined with Glenmark's commercial strength in Emerging Markets, creates complementary access pathways for ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma. At Glenmark, we are committed to expanding access to innovative cancer treatments across Emerging Markets where unmet need and growth potential intersect, said Christoph Stoller, President ' Europe and Emerging Markets, Glenmark Pharmaceuticals. The addition of ISB 2001 is a natural evolution of our oncology strategy. With our deep commercial footprint, strong regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA and TEVIMBRA in India, and rights to commercialize QiNHAYO (envafolimab), a PD-L1 checkpoint inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for patients with difficult-to-treat cancers through ISB 2001. Headquartered in New York, IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Glenmark Pharmaceuticals is a research‐led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
IGI Therapeutics SA and AbbVie enter into an exclusive licensing agreement for ISB 2001

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT' protein platform, for oncology and autoimmune diseases. 'Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,' said Roopal Thakkar, M.D., Executive Vice-President, Research and Development and Chief Scientific Officer, AbbVie. 'This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress.' 'ISB 2001 exemplifies the potential of our BEAT' protein platform to generate effective multispecifics  that may overcome resistance and improve outcomes in hard-to-treat cancers,' said Cyril Konto, M.D., President and CEO of IGI. This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep commitment to delivering meaningful therapies for patients. Our partnership with AbbVie accelerates ISB 2001's path to patients and sharpens our focus on advancing the next generation of BEAT'-enabled assets in oncology.' Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales. Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd spurts 1.6%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1812.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.18% on the day, quoting at 25360.65. The Sensex is at 83104.96, down 0.16%. Glenmark Pharmaceuticals Ltd has gained around 14.34% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.4% in last one month and is currently quoting at 22204.25, up 0.79% on the day. The volume in the stock stood at 3.99 lakh shares today, compared to the daily average of 10.37 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1821.7, up 1.76% on the day. Glenmark Pharmaceuticals Ltd is up 35.42% in last one year as compared to a 4.26% jump in NIFTY and a 9.41% jump in the Nifty Pharma index.The PE of the stock is 28.84 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd up for third straight session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1773.3, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 25484.65. The Sensex is at 83437.68, down 0.31%. Glenmark Pharmaceuticals Ltd has gained around 17.13% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 3.58% in last one month and is currently quoting at 22041.25, up 0.35% on the day. The volume in the stock stood at 2.49 lakh shares today, compared to the daily average of 11.89 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1779.6, up 0.78% on the day. Glenmark Pharmaceuticals Ltd is up 38.34% in last one year as compared to a 4.93% jump in NIFTY and a 11.06% jump in the Nifty Pharma index.The PE of the stock is 28.38 based on TTM earnings ending March 25.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Glenmark Pharmaceuticals launches TEVIMBRA' in India

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA' (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers. TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Live Market Update
Nifty fails to hold 24,850 mark; media shares tumble

The key domestic indices pared all gains and traded with minor losses in mid-morning trade, amid ongoing geopolitical tensions between Israel and Iran. Market direction remains sensitive to geopolitical developments. Investors will closely monitor crude oil prices, developments from the G7 summit and the outcome of the upcoming U.S. Federal Reserve meeting. The Nifty slipped below the 24,850 mark. Media shares witnessed selling pressure for the second consecutive trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex declined 195.99 points or 0.24% to 81,390.04. The Nifty 50 index declined 46.05 points or 0.19% to 24,807.80. In the broader market, the S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.13%. The market breadth was negative. On the BSE, 1,634 shares rose and 2,046 shares fell. A total of 270 shares were unchanged. IPO Update: The initial public offer (IPO) of Arisinfra Solutions received bids for 10,08,216 shares as against 1,30,84,656 shares on offer, according to stock exchange data at 11:24 IST on Wednesday (18 June 2025). The issue was subscribed 0.08 times. The issue opened for bidding on Wednesday (18 June 2025) and it will close on Friday (20 June 2025). The price band of the IPO is fixed between Rs 210 and 222 per share. An investor can bid for a minimum of 67 equity shares and in multiples thereof. Buzzing Index: The Nifty Media index fell 0.83% to 1,709.05. The index declined 1.55% for the two consecutive trading sessions. Dish TV India (down 2.05%), Saregama India (down 1.69%), D B Corp (down 1.38%), Zee Entertainment Enterprises (down 1.31%), Sun TV Network (down 0.89%), Tips Music (down 0.67%), Hathway Cable & Datacom (down 0.47%) and Network 18 Media & Investments (down 0.32%) declined. Stocks in Spotlight: Glenmark Pharmaceuticals rose 0.26%. The company announced that its manufacturing facility in Monroe, North Carolina, USA, has received a Form 483 with five procedural observations from the United States Food and Drug Administration (USFDA). Polycab India shed 0.32%. The company said that it has executed a contract worth Rs 6,447.54 crore with Bharat Sanchar Nigam (BSNL) to act as the project implementation agency (PIA) for the BharatNet project in Karnataka, Goa, and Puducherry. Global Markets: Markets in Asia traded in a mixed fashion on Wednesday, as escalating tensions between Israel and Iran weigh on investor sentiment. Adding fuel to fire, U.S. President Donald Trump is mulling a military strike on Iran, while demanding the country's leader Ayatollah Ali Khamenei 'surrender,' media reports stated. Japan exports in May declined 1.7% year on year, which is lower than the decline of 3.8% that was widely anticipated by the markets. The data comes a day after the Bank of Japan highlighted in its monetary policy statement that the country's growth was likely to 'moderate' on the back of factors like trade, which would lead to a slowdown in overseas economies and a decline in domestic corporate profits. On the Wall Street, all three major averages ended the trading day lower. The Dow Jones Industrial Average lost 299.29 points, or 0.70%, to close at 42,215.80. The S&P 500 shed 0.84% to end at 5,982.72, while the Nasdaq Composite fell 0.91% and settled at 19,521.09. The key indices ended lower ahead of the US Federal Reserve's rate decision, which is due Wednesday afternoon. The U.S. central bank is widely expected to hold rates steady, but investors will be keeping a close eye on Fed Chair Jerome Powell's post-meeting comments. Traders are also watching for policymakers' forecast on rate policy, as the Federal Open Market Committee will be sharing members' 'dot plot' of rate expectations.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Glenmark Pharma's USA facility gets five observations from USFDA

According to a regulatory filing by the company, the USFDA conducted a good manufacturing practices (GMP) inspection at the Monroe site from 9 June to 17 June 2025. Following the conclusion of the inspection, the USFDA has issued a Form 483 with five observations. Glenmark clarified that all the observations are procedural in nature and none pertain to data integrity. The company stated that it will work closely with the USFDA to address the observations and will submit its response within the stipulated timeline. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. The counter shed 0.30% to Rs 1,648.80 on the BSE. Powered by Capital Market - Live

4 weeks agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Glenmark Pharmaceuticals Ltd (GLENMARK) today?

    The share price of GLENMARK as on 16th July 2025 is ₹2224.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The past returns of Glenmark Pharmaceuticals Ltd (GLENMARK) share are
    • Past 1 week: 19.50%
    • Past 1 month: 32.56%
    • Past 3 months: 61.67%
    • Past 6 months: 50.69%
    • Past 1 year: 58.09%
    • Past 3 years: 485.05%
    • Past 5 years: 435.38%

  3. What are the peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK)?
  4. What is the dividend yield % of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The current dividend yield of Glenmark Pharmaceuticals Ltd (GLENMARK) is 0.11.

  5. What is the market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹62820.72 Cr as of 16th July 2025.

  6. What is the 52 week high and low of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The 52-week high of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹2284.80 and the 52-week low is ₹1275.50.

  7. What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) stock?

    The P/E (price-to-earnings) ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) is 60.00. The P/B (price-to-book) ratio is 8.01.

  8. Which sector does Glenmark Pharmaceuticals Ltd (GLENMARK) belong to?

    Glenmark Pharmaceuticals Ltd (GLENMARK) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares?

    You can directly buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares on Tickertape. Simply sign up, connect your demat account and place your order.